SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 8th, 2011 • Cyplasin Biomedical Ltd. • Pharmaceutical preparations • California
THIS AGREEMENT dated as of the 19th day of July 2010 (the “Agreement”) between TANGIERS INVESTORS, LP, a Delaware limited partnership (the “Investor”), and CYPLASIN BIOMEDICAL LTD., a corporation organized and existing under the laws of the State of Nevada the “Company”).
LETTER OF AGREEMENTLetter of Agreement • February 8th, 2011 • Cyplasin Biomedical Ltd. • Pharmaceutical preparations • New York
WHEREAS, Minapharm is engaged in the development and commercial sales of pharmaceutical products within the Arab Republic of Egypt and the MENA region including a version of pegylated interferon-alpha (PEG-IFN) used as a Hepatitis C therapeutic drug,;
EXCLUSIVE LICENSE and OPTION AGREEMENTExclusive License and Option Agreement • February 8th, 2011 • Cyplasin Biomedical Ltd. • Pharmaceutical preparations • Nevada
This Exclusive License Agreement (the “Agreement”) is entered into as of February 7, 2009 (the “Effective Date”), by and between Bioxen Ltd including its affiliates, legal successors and subsidiaries with its principal offices registered as Nautilus House, La Cour des Casernes, St.Helier.Jersey, JE1 3NH, Channel Islands (“Bioxen”) and Cyplasin Biomedical Ltd., a (Nevada corporation), with its principal offices located at Unit 131 Advanced Technology Center, 9650-20th ave., Edmonton, Alberta Canada T6N1G1 including its affiliates, legal successors and subsidiaries, (“Cyplasin”); and collectively referred to as the “Parties”; and
ASSET ASSIGNMENT AGREEMENTAsset Assignment Agreement • February 8th, 2011 • Cyplasin Biomedical Ltd. • Pharmaceutical preparations • Nevada
Dr Joseph Sinkule a resident of Scottsdale, Arizona and C- Virionics Corporation. whose principle address is 42191 N. 111th Place, Scottsdale, Arizona, 85262 (herein collectively the Assignor);
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 8th, 2011 • Cyplasin Biomedical Ltd. • Pharmaceutical preparations • Nevada
This Exclusive License Agreement (the “Agreement”) is entered into as of July 1, 2009 (the “Effective Date”), by and between Virionics Corporation, a Delaware corporation having its principal offices at 42191 N. 111th Place, Scottsdale, Arizona, 85262 (“Virionics”), and Cyplasin Biomedical Inc., with its principal offices located at Unit 131 Advanced Technology Center, 9650-20th Ave., Edmonton, Alberta Canada T6N 1G1 including its legal successors and subsidiaries, (“Cyplasin”); and collectively referred to as the “Parties”; and
